A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

Inclusion Criteria:

• Patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting)

Exclusion Criteria:

• Patients who have had treatment with any investigational therapy within the past 30 days are not eligible.
• Patients who have had a disease or medical condition that is not controlled will not be eligible.
• Patients who are pregnant or breastfeeding are not eligible.